Biopharmaceutical company Immunomedics Ic (IMMU) Monday revealed that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient.
The company stated that TF2 is a bi-specific antibody created using the patented Dock-and-Lock conjugation technology. In addition to targeting the carcinoembryonic antigen expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.
The company further stated that the study results revealed that pretargeting has the potential advantage of delivering increased radiation dose levels selectively to the tumors while minimizing the body's exposure to radiation's harmful side effects.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org